CYTORI THERAPEUTICS, INC. (38)

Browse by Contract Category

Contracts

Cancer Research Grant Contract, effective August 31, 2022, by and between the Cancer Prevention and Research Institute of Texas and Plus Therapeutics, Inc (Filed With SEC on September 22, 2022)
Distribution Agreement, dated September 9, 2022, by and among Plus Therapeutics, Inc. and Canaccord Genuity LLC (Filed With SEC on September 9, 2022)
Registration Rights Agreement, dated August 2, 2022, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 8, 2022)
Plus Therapeutics, Inc. 2020 Stock Incentive Plan, as further amended and restated (Filed With SEC on May 20, 2022)
Patent & Technology License Agreement, dated December 31, 2021, between Plus Therapeutics, Inc. and the University of Texas Health Science Center at San Antonio (Filed With SEC on February 24, 2022)
Purchase Agreement, dated August 2, 2022, by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on August 8, 2022)
Medidata Services Agreement and Statement of Work (Filed With SEC on April 21, 2022)
Form of Notice of Grant and Stock Option Agreement under the 2020 Stock Incentive Plan (Filed With SEC on February 24, 2022)
Distribution Agreement, dated January 14, 2022, by and among Plus Therapeutics, Inc. and Canaccord Genuity LLC (Filed With SEC on January 14, 2022)
LaFrance Employment Agreement, dated September 7, 2021 (Filed With SEC on September 13, 2021)
Plus Therapeutics, Inc., 2020 Stock Incentive Plan, as amended and restated (Filed With SEC on May 20, 2021)
Master Services Agreement between Piramal Pharma Solutions, Inc. and Plus Therapeutics, Inc (Filed With SEC on February 22, 2021)
Distribution Agreement, dated October 23, 2020, by and among Plus Therapeutics, Inc. and Canaccord Genuity LLC (Filed With SEC on October 23, 2020)
Registration Rights Agreement, dated September 30, 2020 by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on October 6, 2020)
Purchase Agreement, dated September 30, 2020 by and between Plus Therapeutics, Inc. and Lincoln Park Capital Fund, LLC (Filed With SEC on October 6, 2020)
Form of Underwriter Warrant Amendment Agreement (Filed With SEC on October 5, 2020)
Plus Therapeutics, Inc., 2020 Equity Incentive Plan (Filed With SEC on June 17, 2020)
Amended and Restated Employment Agreement between Andrew Sims and Plus Therapeutics, Inc (Filed With SEC on May 14, 2020)
Amended and Restated Employment Agreement between Marc Hedrick and Plus Therapeutics, Inc (Filed With SEC on May 14, 2020)
Form of Warrant Amendment Agreement (Filed With SEC on April 23, 2020)
Ninth Amendment to the Loan and Security Agreement, dated March 29, 2020, between Plus Therapeutics, Inc. and Oxford Finance LLC (Filed With SEC on March 30, 2020)
Patent and Know-How License Agreement, dated March 29, 2020, between Plus Therapeutics, Inc. and NanoTx, Corp (Filed With SEC on March 30, 2020)
Second Amendment to the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan, dated February 6, 2020 (Filed With SEC on March 30, 2020)
Description of Securities (Filed With SEC on March 30, 2020)
Employment Agreement between Plus Therapeutics, Inc. and Andrew Sims (Filed With SEC on March 12, 2020)
Employment Agreement between Plus Therapeutics, Inc. and Marc Hedrick (Filed With SEC on March 12, 2020)
Form of Indemnification Agreement (Filed With SEC on February 6, 2020)
Form of Series V Warrant (Filed With SEC on September 16, 2019)
Form of Series U Warrant (Filed With SEC on September 16, 2019)
Form of Underwriting Agreement (Filed With SEC on September 16, 2019)
2014 Equity Incentive Plan of Plus Therapeutics, Inc., as Amended and Restated (Filed With SEC on August 15, 2019)
Eighth Amendment to Loan and Security Agreement, effective as of July 15, 2019, by and between Plus Therapeutics, Inc. and Oxford Finance, LLC (Filed With SEC on August 15, 2019)
Seventh Amendment to Loan and Security Agreement, effective as of April 24, 2019, by and between Cytori Therapeutics, Inc. and Oxford Finance, LLC (Filed With SEC on August 15, 2019)
Seventh Amendment to Loan and Security Agreement, effective as of April 24, 2019, by and between Cytori Therapeutics, Inc. and Oxford Finance, LLC (Filed With SEC on May 14, 2019)
Asset and Share Sale and Purchase Agreement, dated as of April 19, 2019, by and between Cytori Therapeutics, Inc. and Seijir Shirahama (Filed With SEC on April 23, 2019)
Sixth Amendment to Loan and Security Agreement dated March 4, 2019, by and between Cytori Therapeutics, Inc. and Oxford Finance, LLC (Filed With SEC on March 29, 2019)
Fifth Amendment to Loan and Security Agreement dated February 13, 2019, by and between Cytori Therapeutics, Inc. and Oxford Finance, LLC (Filed With SEC on March 29, 2019)
Fourth Amendment to Loan and Security Agreement dated December 31, 2018, by and between Cytori Therapeutics, Inc. and Oxford Finance, LLC (Filed With SEC on February 1, 2019)